Pyrazolylbenzimidazole Derivatives for Selective Anticancer Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapy agents are cytotoxic and pose significant side effects due to lack of selectivity towards cancer cells, necessitating the development of compounds that target metabolic pathways specific to cancer cells with minimal impact on healthy cells, while also ensuring adequate aqueous solubility at physiological pH.
Innovation Solution
Pyrazolylbenzimidazole derivatives are designed to enhance enzymatic and cellular selectivity while maintaining anticancer activity, with specific chemical structures and formulations that include various substituents to optimize drug profiles and solubility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cytotoxic compounds are used for chemotherapy, then anticancer activity is achieved, but side effects and patient tolerance worsen due to lack of selectivity
Solution Approach 1:
The patent applies local quality by designing pyrazolylbenzimidazole derivatives with specific substituent patterns (R1-R5 groups) that create localized interactions with cancer cell metabolic pathways. The molecular structure is optimized to have different properties at different positions, enabling selective targeting of cancer cells while sparing healthy cells through precise enzymatic recognition.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical substituents (R1 = H, Me, Et, CO2Rc, etc.; R3 = morpholinyl, piperazinyl, etc.) to tune the selectivity and activity parameters of the compounds. This allows optimization of the balance between anticancer efficacy and selectivity against healthy cells by adjusting molecular properties.
2Object-affected harmful factors
If drugs are designed to act selectively on cancer cells, then side effects are reduced, but aqueous solubility may worsen
Solution Approach 1:
The patent uses parameter changes by introducing hydrophilic substituents (such as hydroxy, alkoxy, carboxylic acid groups) and adjusting ionization states to improve aqueous solubility while maintaining the selective anticancer activity. The pKa and solubility parameters are optimized through systematic modification of R groups.
Solution Approach 2:
The patent applies composite material principles by creating molecules that combine hydrophobic aromatic cores (for target binding) with hydrophilic substituent groups (for solubility). This composite structure enables both selective anticancer activity and adequate aqueous solubility at physiological pH.
3Reliability
If pyrazolylbenzimidazole derivatives are designed with specific substituents, then enzymatic selectivity is improved, but molecular complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecule into distinct functional modules: a core pyrazolylbenzimidazole scaffold and separate substituent groups (R1-R5) that can be independently optimized. This modular approach allows systematic improvement of enzymatic selectivity by adding specific functional groups without redesigning the entire molecule.
Data Source
AI summary
The invention relates to compounds having the following general formula (I): in which formula (I): R1 and R4 are independently selected from the group consisting of: H, Me, Et, CO2Rc, CH2ORc, ORc, F, Cl and C(=O)NHRd ; in which Rc is chosen from H, (C1-C6)alkyl, substituted (C1-C6)alkyl, (C3-C7)cycloalkyl; substituted (C3-C7)cycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl; and in which Rd is chosen from H, (C1-C6)alkyl, substituted (C1-C6)alkyl, (C3-C7)cycloalkyl, substituted (C3-C7)cycloalkyl, and (C3- C7)heterocycloalkyl comprising from 1 to 3 heteroatoms chosen from N, O and S, optionally substituted; R2and R3 are selected from the group consisting of H, F, ORe and NReRf, with the exception of methoxy and ethoxy, in which: (i) Re and Rf are independently selected from the group consisting of: H, (C1-C6)alkyl, (C1-C6)alkyl substituted with a substituent selected from the group consisting of: ORg, NRhRj, (C3-C7)cycloalkyl and substituted (C3-C7)cycloalkyl, in which: (a) Rg, Rh and Rj are independently selected from the group consisting of: H, (C1-C6)alkyl and substituted (C1-C6)alkyl, or (b) Rg is selected from the group consisting of: H, (C1-C6)alkyl and substituted (C1-C6)alkyl, and Rh and Rj form a ring containing one to three heteroatoms chosen from N, O and S, or (ii) Re and Rf form an optionally substituted heterocycle containing from one to three heteroatoms chosen from N, O and S; R5 is selected from the group consisting of: NMeEt, NH(iPr), NEt2, N(iPr2), NEt(iPr), pyrrolidinyl, piperidinyl, morpholinyl, N-methylpiperazinyl, NHCy, NCy2, NMe(iPr), NH(tBu), NH(iBu), N(nBu)2, piperazinyl, NH(Et), N(nPr)2 and NEt(iPr).